

The Promise and Perils of Cellular TherapiesJuly 16, 2019 |
New “living drugs”—made from a patient’s own cells—can cure once incurable cancers. But can we afford them?
Quick Read
The Promise and Perils of Cellular TherapiesJuly 16, 2019 |
New “living drugs”—made from a patient’s own cells—can cure once incurable cancers. But can we afford them?
Quick ReadAs someone who has lived with spinal muscular atrophy for all 30 years of my life, I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price: $2.125 million
Quick Read
When a Treatment Costs $450,000 or More, It Had Better WorkApril 24, 2019 |
Some biotech companies are offering a new way to soften the shock of drug prices: Insurers pay only if the patient improves
Quick Read
Prominent ‘Right-To-Try’ Advocate Is Getting Treatment Under New LawFebruary 6, 2019 |
One of the namesakes of the federal “right-to-try” law confirmed Tuesday that he gained access to an experimental treatment thanks to the new law
Quick ReadAuthors, including our Jeremy Sugarman, offer a call to action, ‘Companies that develop and distribute tools for genome editing have a responsibility to construct and implement policies and procedures to protect the integrity of science, to educate their employees to make certain that all research conducted within the company adheres to the highest ethical standards’
Quick Read
We May Soon Have our First $1m DrugOctober 13, 2017 |
Who will pay for it? And how?
Quick ReadThe approval of gene therapy for leukemia, expected in the next few months, will open the door to a radically new class of cancer treatments
Quick ReadThe high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday
Quick Read